OBJECTIVE: To report a case of a neuroendocrine differentiation in a prostate cancer patient, a rare subtype.
METHODS: We describe the case of a patient diagnosed with adenocarcinoma of the prostate initially, who presented hematuria due to disease progression with neuroendocrine differentiation despite androgen-deprivation therapy (ADT ).
DISCUSSION: Prostate cancer is the most common tumor in men. Histologically they are diagnosed as adenocarcinomas, which followed by ADT for a long time, develop neuroendocrine differentiation (NED ).
CONCLUSIONS: The prognostic significance of NED remains controversial. We must think in neuroendocrine differentiation in ADT-treated patient with disease progression and low PSA.
Written by:
Moratalla Charcos LM, Pastor Navarro T, Cortes Vizcaino V, Osca Garcia JM, Gil Salom M. Are you the author?
Urology Department, Hospital Universitario Dr.Peset, Valencia, Spain.
Reference: Arch Esp Urol. 2013 May;66(4):368-371.
PubMed Abstract
PMID: 23676541
Article in English, Spanish.
UroToday.com Prostate Cancer Section
